MA53548B1 - Formulations antiparasitaires de goût agréable - Google Patents

Formulations antiparasitaires de goût agréable

Info

Publication number
MA53548B1
MA53548B1 MA53548A MA53548A MA53548B1 MA 53548 B1 MA53548 B1 MA 53548B1 MA 53548 A MA53548 A MA 53548A MA 53548 A MA53548 A MA 53548A MA 53548 B1 MA53548 B1 MA 53548B1
Authority
MA
Morocco
Prior art keywords
tasting
pleasant
composition
antiparasitic formulations
animal
Prior art date
Application number
MA53548A
Other languages
English (en)
Other versions
MA53548A (fr
Inventor
Sachin Pundlik Kolhe
Supriya Gautam THAKUR
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67982187&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53548(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MA53548A publication Critical patent/MA53548A/fr
Publication of MA53548B1 publication Critical patent/MA53548B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)

Abstract

La présente invention concerne une composition à mâcher dure au goût agréable comprenant une quantité thérapeutiquement efficace d'une isoxazoline pharmaceutiquement acceptable, une lactone macrocyclique stabilisée, une forme saline acceptable de pyrantel, au moins un aliment naturel d'origine animale, et au moins un excipient acceptable du point de vue vétérinaire; et des procédés de traitement ou de prévention d'une infection ou d'une infestation parasitaire chez un animal en ayant besoin au moyen de ladite composition.
MA53548A 2018-09-05 2019-09-03 Formulations antiparasitaires de goût agréable MA53548B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862727018P 2018-09-05 2018-09-05
PCT/US2019/049279 WO2020051106A1 (fr) 2018-09-05 2019-09-03 Formulations antiparasitaires de goût agréable
EP19769675.0A EP3846786B1 (fr) 2018-09-05 2019-09-03 Formulations antiparasitaires de goût agréable

Publications (2)

Publication Number Publication Date
MA53548A MA53548A (fr) 2021-07-14
MA53548B1 true MA53548B1 (fr) 2024-12-31

Family

ID=67982187

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53548A MA53548B1 (fr) 2018-09-05 2019-09-03 Formulations antiparasitaires de goût agréable

Country Status (27)

Country Link
US (1) US11896594B2 (fr)
EP (2) EP3846786B1 (fr)
JP (1) JP7241170B2 (fr)
KR (1) KR102554130B1 (fr)
CN (1) CN113038937A (fr)
AU (1) AU2019336663B2 (fr)
CA (1) CA3109543C (fr)
CL (1) CL2021000474A1 (fr)
DK (1) DK3846786T3 (fr)
ES (1) ES3002764T3 (fr)
FI (1) FI3846786T3 (fr)
HR (1) HRP20241712T1 (fr)
HU (1) HUE069712T2 (fr)
IL (1) IL281206B2 (fr)
LT (1) LT3846786T (fr)
MA (1) MA53548B1 (fr)
MD (1) MD3846786T2 (fr)
MX (1) MX2021002606A (fr)
NZ (1) NZ774180A (fr)
PH (1) PH12021550338A1 (fr)
PL (1) PL3846786T3 (fr)
PT (1) PT3846786T (fr)
RS (1) RS66315B1 (fr)
SI (1) SI3846786T1 (fr)
SM (1) SMT202400523T1 (fr)
WO (1) WO2020051106A1 (fr)
ZA (1) ZA202100950B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
CN119157876A (zh) 2017-12-15 2024-12-20 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
WO2020202111A1 (fr) * 2019-04-04 2020-10-08 Tarsus Pharmaceuticals, Inc. Parasiticides systémiques à base d'isoxazoline pour le traitement ou la prophylaxie d'une maladie virale et à vecteur
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
JP7724845B2 (ja) 2020-07-24 2025-08-18 エランコ・ユーエス・インコーポレイテッド イソオキサゾリン化合物及びその中間体を作製するための方法
MX2023002666A (es) * 2020-09-03 2023-04-20 Elanco Tiergesundheit Ag Formulaciones masticables.
KR20230061465A (ko) 2020-09-04 2023-05-08 엘랑코 유에스 인코포레이티드 기호성 제형
CA3211576A1 (fr) * 2021-03-11 2022-09-15 In The Bowl Animal Health, Inc. Aliment oral canin et procedes de lutte contre les infestations par les tiques chez un chien
KR20240051920A (ko) * 2021-06-25 2024-04-22 인 더 보울 애니멀 헬스, 인크. 고양잇과의 진드기 감염을 구제하기 위한 경구용 고양잇과 사료 및 방법
KR20240025534A (ko) * 2021-06-25 2024-02-27 인터벳 인터내셔널 비.브이. 맛우수한 수의학적 조성물
CN115671288B (zh) * 2021-07-21 2024-05-10 瑞普（天津）生物药业有限公司 一种抗寄生虫复方软咀嚼药物制剂及其制备方法与应用
CN115671040B (zh) * 2021-07-21 2024-02-27 瑞普（天津）生物药业有限公司 一种控制动物寄生虫感染的外用制剂
CN116953130A (zh) * 2022-04-12 2023-10-27 洛阳惠中兽药有限公司 含有氟雷拉纳的药物组合物的溶出方法及其应用
PE20231574A1 (es) 2023-02-24 2023-10-04 Agrovet Market S A Composicion farmaceutica que comprende fluralaner, moxidectina y praziquantel para el tratamiento de infestaciones parasitarias en animales menores

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197215B1 (fr) * 2000-10-10 2006-03-22 Wyeth Compositions anthelmintiques
AU2006100657C4 (en) * 2006-05-15 2009-09-10 Wyeth Stabilised formulation
UA108641C2 (uk) * 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
CN104168900A (zh) 2012-02-06 2014-11-26 梅里亚有限公司 包含全身性地起作用的活性剂的杀寄生虫口服兽用组合物、方法及其用途
BR112014024833B1 (pt) * 2012-04-04 2022-10-04 Intervet International B.V. Produto farmacêutico veterinário mastigável macio, processo para sua fabricação e seu uso, bem como uso de pamoato de sódio
CN104602529B (zh) * 2012-09-07 2016-11-02 硕腾服务有限责任公司 螺环异噁唑啉杀寄生虫组合
WO2014095845A1 (fr) * 2012-12-19 2014-06-26 Bayer Animal Health Gmbh Comprimés présentant une appétence améliorée et une stabilité au stockage satisfaisante
PE20151726A1 (es) 2013-04-12 2015-11-18 Zoetis Services Llc Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles
CA2965524C (fr) 2014-11-03 2020-04-14 Zoetis Services Llc Composition veterinaire a macher appetissante
EP3389628A4 (fr) 2015-12-19 2019-08-07 Dixit, Manesh A. Formulations pharmaceutiques de comprimés mous à mâcher
RU2657508C1 (ru) 2017-07-04 2018-06-14 Александр Анатольевич Хахалин Комбинированное противопаразитарное средство для лечения и профилактики гельминтозов и арахноэнтомозов плотоядных животных

Also Published As

Publication number Publication date
CA3109543C (fr) 2023-05-23
FI3846786T3 (fi) 2025-01-14
SMT202400523T1 (it) 2025-01-14
PT3846786T (pt) 2025-01-08
CN113038937A (zh) 2021-06-25
WO2020051106A1 (fr) 2020-03-12
US20210220360A1 (en) 2021-07-22
IL281206B2 (en) 2025-08-01
EP4487846A2 (fr) 2025-01-08
MD3846786T2 (ro) 2025-04-30
PH12021550338A1 (en) 2021-10-04
MA53548A (fr) 2021-07-14
LT3846786T (lt) 2025-01-10
ES3002764T3 (en) 2025-03-07
RS66315B1 (sr) 2025-01-31
AU2019336663B2 (en) 2023-09-14
MX2021002606A (es) 2021-05-12
CA3109543A1 (fr) 2020-03-12
CL2021000474A1 (es) 2021-07-19
JP7241170B2 (ja) 2023-03-16
AU2019336663A1 (en) 2021-03-11
EP3846786A1 (fr) 2021-07-14
EP3846786B1 (fr) 2024-11-13
DK3846786T3 (da) 2024-12-02
US11896594B2 (en) 2024-02-13
JP2022501329A (ja) 2022-01-06
BR112021004218A2 (pt) 2021-05-18
ZA202100950B (en) 2024-09-25
SI3846786T1 (sl) 2025-04-30
IL281206B1 (en) 2025-04-01
EP4487846A3 (fr) 2025-03-19
HUE069712T2 (hu) 2025-04-28
KR102554130B1 (ko) 2023-07-12
IL281206A (en) 2021-04-29
KR20210039427A (ko) 2021-04-09
NZ774180A (en) 2023-04-28
PL3846786T3 (pl) 2025-03-03
HRP20241712T1 (hr) 2025-02-14

Similar Documents

Publication Publication Date Title
EP4487846A3 (fr) Formulations antiparasitaires de goût agréable
Cembella Chemical ecology of eukaryotic microalgae in marine ecosystems
Titball et al. Burkholderia pseudomallei: animal models of infection
Cho et al. In vivo inhibition of Porphyromonas gingivalis growth and prevention of periodontitis with quorum‐sensing inhibitors
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
TNSN03155A1 (fr) Vaccination unidose avec mycoplasma hyopneumoniae
EA200701113A1 (ru) Макролиды
FR3076997B1 (fr) Extrait obtenu a partir de plusieurs plantes pour son utilisation dans la prevention et/ou le traitement des maladies chroniques inflammatoires de l'intestin
Goulas et al. A structure-derived snap-trap mechanism of a multispecific serpin from the dysbiotic human oral microbiome
ES3055402T3 (en) Compositions for disrupting biofilm formation and for treating biofilm-related disorders
El Hammed et al. Use of allicin as feed additive to enhance vaccination capacity of Clostridium perfringens toxoid in rabbits
FR3081686B1 (fr) Composition alimentaire comprenant de la phycocyanine
JP6709395B2 (ja) 冷水病ワクチン及び冷水病の予防方法
ATE539153T1 (de) Primaten t-lymphotrophische viren
Awad et al. Efficacy of ciprofloxacin and clove extract on bacterial infection of clarias gariepinus
UA157558U (uk) Спосіб підвищення імунорезистентності котів при респіраторних інфекціях
AU2021234626B2 (en) Compositions for disrupting biofilm formation and for treating biofilm-related disorders
Gupta Factors affecting the virulence of Photobacterium damselae subsp. damselae to yellowtail kingfish (Seriola lalandi)
조영재 In vivo Inhibition of Porphyromonas gingivalis Growth and Prevention of Periodontitis With Quorum-Sensing Inhibitors
PFISTER Copyright© 2018 C HIMONAS, S SOTIRAKI, E PAPADOPOULOS, K PFISTER
Daigneault et al. Penicillin Concentrations in Serum and Milk Following Administration of Procaine Penicillin G By Different Route at Different Dosage
Abdurakhim et al. Nematodes in the digestive tracts of domestic ruminants in Uzbekistan
Ceylan et al. Some biological activities of five Asteraceae species from Turkey
Krivosheina Morpho-ecological characteristic of immature stages of the genus Mydaea (Diptera, Muscidae)
Puzyr et al. Wood luminescence as marker of tree Armillaria infection.